Please login to the form below
Multi-level Segmentation Solution
Our client has an established product for multiple indications. They wanted to create a HCP segmentation typing tool which could be implemented in-field to help classify physicians across two different therapeutic areas. There was rationale to suggest that because the two therapeutic areas are pathologically different, then two separate typing tools would be required. However, it was also argued that a one segment solution would be most suitable as physicians fundamentally have the same attitudes, irrespective of the disease they are treating. Additionally, our client would be able to implement a single segmentation tool into its core business much more efficiently than two separate tools. The challenge was to therefore decide whether a one tool or two tool solution would be most suitable.
Find out more: https://www.researchpartnership.com/news/2017/08/multi-level-segmentation-solution/
Company Details
Research Partnership
+44 (0)20 8069 5000
Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom
Latest content on this profile
- Healthcare in the age of AI: How will artificial intelligence impact future decision-making?
- Authored by: Constanza Salas, Jhon Galindo and Rachel Howard
Research Partnership
- Therapy Watch launches new tracker covering Postpartum Depression
- The new Therapy Watch Postpartum depression (PPD) study is the first tracker in the series to cover Psychiatry
Research Partnership
- Value-based pricing reform: Strengthening the ‘front door’ to the Colombian pharmaceutical market
- Authored by: Marc Garcia and Tania Rodrigues
Research Partnership
- Infographic: Rare Diseases in China
- How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.
Research Partnership
- New syndicated COPD report now available
- Living with COPD 2023
Research Partnership
- Man vs microbe: the fight against antimicrobial resistance
- How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics.
Research Partnership
